Alzheimer's Disease Drug Market is Declining and it is Expected to fall till 2016
MUMBAI, India, December 9, 2013 /PRNewswire/ --
Bharat Book Bureau presents Alzheimer's Pipeline Drugs Review, Alzheimer's disease Drug Market & Forecast - Global Analysis. This report Alzheimer's disease drug market is on the curvature stage. Since 2003, there is not any single "magic bullet" launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. If successful, they will be in a position to command premium prices and tap the existing opportunity. Lot of drugs has failed in Phase III stage thus putting a greater impact on Alzheimer's disease drug market. (http://www.bharatbook.com/healthcare-market-research-reports/alzheimers-pipeline-drugs-review-alzheimers-disease-drug-market-forecast-global-analysis.html)
(Logo: http://photos.prnewswire.com/prnh/20130128/590935 )
From the year 2009 Alzheimer's disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimer's drugs from the year 2017 onwards, Alzheimer's disease drug market is expected to revive in the coming years. However due to absence of exact potential drugs there will always remain a huge Unmet Alzheimer's Drug Market. For the year 2018 Alzheimer's disease Drug Market will be just 10% of Unmet Alzheimer's Disease Drug Market.
"Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast - Global Analysis" provides a comprehensive assessment of the fast-evolving, high-growth Global Alzheimer's Disease Market. This 110 page report with 29 Figures and 11 Tables studies the Global Alzheimer's Disease Drug Market.
Present & Pipeline Drugs Studied in this Report
- Namenda
- Ebixa
- Axura
- Aricept
- Nootropil
- Exelon
- Memary
- Solanezumab
- LuAe58054
This report contains 10 chapters.
Chapter 1: Executive Summary
Chapter 2: This Chapter is divided into 2 parts
- Alzheimer's Disease Drug Market & Forecast data available from 2003 to 2018
- Unmet Alzheimer's Disease Drug Market & Forecast (Market Potential) data available from 2010 to 2018. (Unmet market is the potential market which could have been achieved if right drug have been introduced in the market)
Chapter 3: This chapter talks about drugs which has failed while in Clinical trials
Chapter 4: This chapter provides Market Share of Alzheimer's Disease Drug from 2003 to 2018. All the 9 Alzheimer's drug mentioned above have been covered in this chapter.
Chapter 5: This chapter talks about Alzheimer's Drugs performance. All important drugs mentioned above past, present & future market data available from 2003 to 2018.
Chapter 6: Pipeline drugs (Solanezumab, LuAE58054, Gantenerumab, Crenezumab, TRx0237 (LMTX), MK-8931, ABT-126, and AZD-1446) have been analyzed in this chapter. All drugs have been analyzed from 5 view points:
- Clinical Development Stage
- Pipeline Drug Sales Performance
- Recent Clinical Development
- Different Companies Deal
- Investment
Chapter 7: This chapter speaks of Alzheimer's Drugs Company deals in four areas
- Strategic Alliances in Alzheimer's Disease Drug Market
- Licensing Agreement in Alzheimer's Disease Drug Market
- Collaboration Deal in Alzheimer's Disease Drug Market
- Merger & Acquisition in Alzheimer's Disease Drug Market
Chapter 8: This chapter studies Funding in Alzheimer's disease Drugs Research. We have covered 5 institutes which provides fund for the research.
Chapter 9: This chapter studies Growth Factors Driving the Alzheimer's disease Drug Market.
Chapter 10: This chapter studies Challenges/Hindrances faced by Alzheimer's disease Drug Market.
Table of Contents
Executive Summary
Worldwide - Alzheimer's Disease Drug Market Analysis
- Alzheimer's Disease Drug Market & Forecast
- Unmet Alzheimer's Disease Drug Market & Forecast (Market Potential)
Failed Alzheimer's Drugs
- Dismal Results but Still Trying Again
Worldwide - Alzheimer's Disease Drug Market Share & Forecast
- Worldwide - Alzheimer's Drug Brands Market Performance
- Exelon (Rivastigmine) - Past, Present & Future Market
- Aricept (Donepezil) - Past, Present & Future Market
- Memantine (Namenda, Ebixa, Axura, Memary) Past, Present & Future Market
- Namenda (Memantine) - Past, Present & Future Market
- Ebixa (Memantine) - Past, Present & Future Market
- Axura (Memantine) - Past, Present & Future Market
- Memary (Memantine) - Past, Present & Future Market
- Nootropil (Piracetam) - Past, Present & Future Market
Pipeline Drugs Analysis in Alzheimer's disease Market
- Solanezumab (LY2062430) - Eli Lilly
- Clinical Development Stage
- Phase - II
- Phase - III
- Solanezumab Drug Sales (2017 - 2020)
- Recent Clinical Development
LuAE58054 - Lundbeck
- Clinical Development Stage
- Phase - II
- LuAE58054 Drug Sales (2017 - 2018)
- Deal on LuAE58054
Gantenerumab - Roche
- Clinical Development Stage
- Phase - I
- Phase - II & III
- Phase - III
- Investment in Gantenerumab Drug
Crenezumab - Genentech
- Clinical Development Stage
- Phase - II
- Investment in Crenezumab Drug
TRx0237 (LMTX) - TauRx Therapeutics Ltd.
- Clinical Development Stage
- Phase - II
- Phase - III
- Investment in TRx0237 (LMTX) Drug
MK-8931 - Merck
- Clinical Development Stage
- Phase - II/III
ABT-126 - AbbVie
- Clinical Development Stage
- Phase - I
- Phase - II
AZD-1446 - Targacept/AstraZeneca
- Clinical Development Stage
- Phase - I
- Recent Development
M&A, Licensing Agreement, Strategic Alliances & Collaboration Deals in Alzheimer's disease Drug Market
- Strategic Alliances in Alzheimer's Disease Drug Market
- Licensing Agreement in Alzheimer's Disease Drug Market
- Collaboration Deal in Alzheimer's Disease Drug Market
- Merger & Acquisition in Alzheimer's Disease Drug Market
Funding in Alzheimer's disease Drugs Research
- National Institute of Health
- Alzheimer's Association
- Cure Alzheimer's Fund
- Alzheimer's Drug Discovery Foundation
- Bright Focus Foundation [formerly American Health Assistance Foundation (AHAF)]
Key Drivers of Growth in Global Alzheimer's disease Drug Market
- Aging Population
- Global Ageing Indicators
- Population Aged 60 or Over: World and Development Regions, 1950 - 2050
- Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 - 2050
- Unmet Medical Needs
- The Launches of New Drugs Solanezumab, LuAE58054, Gantenerumab & TRx0237 Will Boost the Alzheimer's Market Through 2018
- Future Drugs for Disease Modification in Alzheimer's Disease
Key Challenges in the Global Alzheimer's disease Drug Market
- Lack of Validated Targets & Lack of Animal Models
- Barriers in the Design and Implementation of Clinical Trials
- Barriers in Academia & Regulatory Issues
- Alzheimer's Drug Failure: Insinuation for Future R&D in Neuroscience
- Costly Alzheimer's Drug Development Dissuade Drug Companies
- Research Setbacks and Stepping Stones
Request for sample pages: http://www.bharatbook.com/RequestSample.asp?pid=199411
For more information on the report: http://www.bharatbook.com/healthcare-market-research-reports/alzheimers-pipeline-drugs-review-alzheimers-disease-drug-market-forecast-global-analysis.html
Related Reports:
- US Alzheimer Drug Pipeline Analysis
- Disease and Therapy Review: Alzheimer Disease
- Global Markets and Manufacturing Technologies for Protein Drugs - Focus on Blood Factors, Vaccines and Peptide Antibiotics
- 2014 Analysis of the US Drugs of Abuse Point-of-Care Testing Market: Physician Offices, Emergency Rooms, Ambulatory Care Centers
Related Category:
About Bharat Book Bureau
Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.
Contact us:
Poonam
Bharat Book Bureau
USA/Canada - 1-866-279-8368 (Toll free)
India: +91-22-27810772, 27810773
Blog: http://blog.bharatbook.com
E: [email protected]
W: http://www.bharatbook.com
SOURCE Bharat Book Bureau
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article